Physician profile
Amanda Hasley
NPI 1801578547
$1,689.39
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $396 · 2024: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $393.92 | 2023-2024 | |
| Lilly USA, LLC | $165.22 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $140.89 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $113.34 | 2023-2024 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $82.14 | 2023-2024 | Auvelity, Sunosi |
| Pfizer INC. | $81.89 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $74.68 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.82 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $64.31 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $64.27 | 2023-2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $63.46 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.03 | 2023-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.45 | 2024 | Caplyta |
| Corium, LLC | $43.10 | 2024 | Azstarys, Azstarys |
| Lundbeck LLC | $41.96 | 2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.57 | 2024 | Spravato |
| Inspire Medical Systems, INC. | $24.96 | 2023 | Inspire |
| Vertos Medical, INC. | $24.02 | 2024 | Mild Device Kit |
| Phathom Pharmaceuticals, INC. | $21.77 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $19.55 | 2024 | Trintellix |
| Tolmar, INC. | $16.87 | 2024 | |
| Amgen INC. | $14.51 | 2024 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $13.66 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.